Dechra’s Vetoryl Receives FDA Approval

The U.S. FDA has approved Dechra Veterinary Products’ Vetoryl Capsules.

The U.S. Food and Drug Administration has approved Dechra Veterinary Products’ Vetoryl (trilostane) Capsules.

The product is intended for treating pituitary-dependent hyperadrenocorticism, which comprises the majority of cases of Cushing’s syndrome in dogs.

Vetoryl also has received the designation status as a Minor Use Drug for treatment of hyperadrenocorticism caused by adrenal tumors, the first drug to receive approval for this indication and the first drug to receive a Minor Use designation in dogs, according to the company.

Dechra is based in Overland Park, Kan.


Leave a Comment


Your email address will not be published. Required fields are marked *


Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.